Tirzepatide 60mg

Tirzepatide is a synthetic peptide that activates both the GLP-1 and GIP receptors, producing simultaneous engagement of the two principal incretin pathways. This combined receptor profile underpins its role in research into glucose homeostasis, weight regulation and pancreatic hormone signalling, and has established it as one of the most-studied dual incretin agonists in modern metabolic research.

This 60mg lyophilised peptide vial is supplied for reconstitution with bacteriostatic water and is intended for extended research protocols, larger animal models and institutional laboratories where higher per-vial quantities reduce handling overhead and improve unit cost across long-running comparative studies.

Research Applications • Long-duration studies of incretin receptor signalling and metabolic adaptation • High-throughput screening of dual agonist activity in cellular models • Extended in vivo investigations of body composition and glycaemic control • Reference standard work in comparative GLP-1, GIP and dual-agonist pharmacology

Specification • Identity: Tirzepatide (CAS 2023788-19-2) • Molecular weight: 4813.52 g/mol • Purity: 99.5%+ verified by HPLC and Mass Spectrometry • Format: lyophilised peptide vial — reconstitute with bacteriostatic water before use • Storage: store lyophilised at -20°C; once reconstituted, refrigerate at 2-8°C and use within 4-6 weeks; protect from light

For research use only — not for human consumption.